[bradykinin]{.smallcaps} (BK) plays an important role in pre- and postconditioning and in cardiac protection during ischemia-reperfusion ([@B3], [@B10], [@B14]). BK has been demonstrated in the heart or cardiomyocytes to inhibit apoptosis ([@B49]), to activate ATP-sensitive K^+^ channels, and to induce the generation of nitric oxide and reactive oxygen species ([@B8], [@B11]). The key link between BK and changes in these cardioprotective effectors through signaling molecules and protein phosphorylation and the subsequent functional changes is poorly understood. One potential pathway to mediate BK signaling is through the p21-activated kinase-1 (Pak1). Pak1 is a member of a highly conserved family of Ser/Thr protein kinases that are downstream effectors of the small G proteins, Cdc42, and Rac1 ([@B32]). Constitutively active Pak1 induces cytoskeletal reorganization including the loss of stress fibers and the dissolution of focal adhesion complexes ([@B31]). In cardiac myocytes, we reported that constitutively active Pak1 induced the dephosphorylation of cardiac troponin I (cTnI) through the activation of protein phosphatase 2A (PP2A) ([@B22]). In myocytes expressing constitutively active Pak1, the Ca^2+^ sensitivity of myofilament tension increased as expected with the dephosphorylation of cTnI ([@B22]). Pak1 expression also blunted the sarcoplasmic reticulum (SR) Ca^2+^ release in the presence of isoproterenol (Iso) with no coincident loss of caffeine-releasable Ca^2+^, indicating that the action was on the release mechanism ([@B42]). Pak1 inhibited L-type Ca^2+^ channels and delayed rectifier K^+^ channel activities in the presence of Iso in sinoatrial nodal cells ([@B20]). Pak1 may also mediate a cardioprotective effect by FTY720 in isolated rat heart subjected to ischemia and reperfusion ([@B12]).

Although there is evidence that Pak1 might be a downstream effector of BK ([@B25]) in nonmuscle cells, there is no direct evidence that Pak1 is activated by BK in cardiac myocytes. BK is a peptide, which acts in a paracrine and autocrine manner as the major signaling factor in the kalikrein kinin system ([@B3]). BK acts in various systems including alterations in function of heart ([@B9]), kidney ([@B40]), and blood vessels ([@B33], [@B36]), where it binds to B~2~ kinase receptor, a G protein-coupled receptor ([@B35]). In patients with essential hypertension, treatment with angiotensin-converting enzyme inhibitors increased the plasma BK level associated with reduced blood pressure ([@B24]). Thus BK is significant clinically, though the intracellular mechanisms of its function in cardiac myocytes remain unclear. In experiments reported here, we show evidence that the treatment of cardiac myocytes with BK induces an activation of Pak1 that is associated with the dephosphorylation of cTnI, phospholamban (PLB), and slowed the relaxation of Ca^2+^ transients in cardiac myocytes stimulated with Iso.

MATERIALS AND METHODS
=====================

### Bradykinin.

All experiments employed BK~1--9~ (B-3259, Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg), which was purchased from Sigma (St. Louis, MO).

### Isolation and culture of Ca^2+^-tolerant cardiac ventricular myocytes.

Cardiac ventricular myocytes were isolated from the hearts of adult male rats, 2 to 3 mo old, using a collagenase perfusion method as previously described ([@B14]). All investigations conformed to the *Guide for the Care and Use of Laboratory Animals*, published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996) and were approved by the Institutional Animal Care and Use Committee of the University of Illinois at Chicago. Two hours before plating the myocytes, the culture dishes were coated with laminin at 10 μg/ml. The cells were first cultured for 2 h in DMEM (D6421, Sigma) plus 10% FBS for cell attachment. The medium was then changed to serum-free DMEM, and the cells were cultured overnight. The cultured ventricular myocytes were treated with vehicle or BK at 0, 0.1, 1, and 10 μM for 10 min before the preparation of the samples.

### AdPak1 construction, viral amplification, and plaque assays.

The preparation of recombinant adenovirus that expresses constitutively active Pak1 (AdPak1) was described previously ([@B22]). The viral titer (in plaque forming units/ml) and the multiplicity of infection were determined by standard techniques ([@B2]).

### Metabolic labeling of cardiac myocytes with \[^32^P\].

The levels of protein phosphorylation in myocyte preparations were determined using a protocol modified from that described by Fentzke et al. ([@B13]). The freshly isolated adult rat cardiac myocytes were allowed to settle onto 35-mm tissue culture plates coated with laminin as described in *Isolation and culture of Ca*^*2+*^*-tolerant cardiac ventricular myocytes* and were cultured for 2 h in DMEM with 10% FBS. Viral infection (multiplicity of infection of 100) was carried out when the media was exchanged for serum free. The cells were infected with AdPak1 or AdLacZ for 8 h, in which time the level of transgene expression was substantial, and DMEM was replaced with Na-HEPES phosphate-free buffer containing (in mM) 1.0 CaCl~2~, 4.8 KCl, 1.2 MgSO~4~, 132 NaCl, 10 HEPES, 2.5 Na-pyruvate, and 10 glucose (pH 7.4) with 0.1 mCi \[^32^P\]orthophosphate for 30 min at room temperature. At 30 min of incubation in buffer containing \[^32^P\]orthophosphate, Iso or BK was added and was incubated for 2 min more. The cells were then washed twice with the Na-HEPES solution with 1 mM CaCl~2~. Two minutes after adding vehicle, Iso, or Iso + BK, we added an equal volume of SDS-stop solution containing (in mM) 1 DTT, 30 Tris·HCl, and 3 EDTA with 6% SDS, 15% glycerol, and a trace of bromophenol blue. An aliquot of cells containing 50 μg protein, as determined using the Lowry method, was analyzed by SDS-PAGE. The samples were first boiled for 10 min, and PAGE was performed using either 12% or a linear 5--20% polyacrylamide gradient gel as previously described ([@B13]).

### Western blot analysis and immunoprecipitation.

To prepare cell lysates for Western blot analysis, cultured adult cardiac myocytes were incubated with a modified radioimmunoprecipitation assay buffer containing 20 mM Tris·HCl (pH 7.4), 0.5% deoxycholate, 0.1% SDS, and 0.1% Triton X-100. Cellular and nuclear debris were removed by centrifugation at 1,200 *g* for 15 min, and the pellet was resuspended in 50 μl of lysis buffer and 50 μl of sample buffer containing 37% deionized water, 13% 0.5 M Tris·HCl (pH 6.8), 26% glycerol, 21--10% sodium dodecylsulfate, and 2--0.5% (wt/vol) bromophenol blue. For immunoprecipitation, the same procedures were used as described previously ([@B22]).

Primary antibodies used included the following: Pak1 (Cell Signaling Technology, Hitchin, UK; and SC-881, Santa Cruz), PLB (No. 05-205, Upstate) and phospho-PLB (No. 07-052, Upstate), and polyclonal antibody against residues surrounding Thr423 of endogenous PAK1 protein raised in rabbit (Cell Signaling Technology).

### Labeling of proteins for immunofluorescence.

For immunolabeling, coverslips containing myocytes were washed twice with PBS, and the cells were fixed with 2% paraformaldehyde. The cells were washed twice (5 min) with PBS containing 0.25% NH~4~Cl, 0.01% saponin, and 0.02% NaN~3~. The cells were then coated with PBS containing 0.5% BSA, 0.01% saponin, and 0.02% NaN~3~. The primary antibody was added in coating reagent and incubated for 30 min. The cells were washed three times in PBS containing 0.05% saponin and 0.02% NaN~3~ and incubated in secondary antibody for 15 min in PBS containing 0.5% BSA, 0.01% saponin, and 0.02% NaN~3~ and then washed three times (5 min) with PBS containing 0.01% saponin and 0.02% NaN~3~. Anti-Pak1 (α-Pak) polyclonal antibody of rabbit origin was from Santa Cruz Biotechnology (Cat No. SC-881). For immunofluorescence studies, we used a 1:50 dilution, and for Western blot analysis, a 1:200 dilution. The secondary antibody (1:200 dilution) was fluorescein isothiocyanate-conjugated anti-rabbit IgG of goat origin (Sigma, Cat No. F-9887). Rhodamine-conjugated phalloidin was purchased from Sigma (Cat No. 1951). Images were acquired using a Bio-Rad laser scanning confocal microscope Radiance 2000 equipped with a ×60 water immersion objective. A 488- and a 568-nm beam from an argon-krypton laser was used for excitation. The detection of the emissions from green and red fluorescence was through HQ515/30 and HQ590/70 filters, respectively. The collected images were processed using LaserPix version 4.0 (Bio-Rad).

### Intracellular Ca^2+^ concentration imaging.

Adult rat ventricular myocytes were loaded with the Ca^2+^-indicator fluo-4 by exposure for 20 min at room temperature to 1 ml standard Tyrode solution containing 10 μM fluo-4 acetoxymethyl ester (Molecular Probes, Eugene, OR) made from a DMSO stock solution. A minimum of 15 min was allowed for de-esterification of the indicator. Coverslips containing single myocytes were mounted on the stage of an inverted Nikon microscope and continuously perfused with a solution containing (in mM) 137 NaCl, 5 KCl, 10 HEPES, 1 MgCl~2~, and 1 CaCl~2~ (pH 7.4). In some experiments, 100 nM Iso or 1 μM propranolol were added to the perfusate. The indicator was excited with the 488-nm line of an argon ion laser attached to the microscope via a confocal laser-scanning unit (Radiance 2100, Bio-Rad) equipped with a ×60 water immersion objective. Emitted fluo-4 fluorescence was measured at wavelengths \> 515 nm. Linescan images were recorded from a central focal plane. Intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) images were calculated according to the following formula ([@B4]): \[Ca^2+^\]~i~ = *K*~d~*R*/(*K*~d~/\[Ca^2+^\]~rest~ − *R* + 1), where *R* is the fluorescence (*F*) normalized to resting (*F*~0~) fluorescence (*R* = *F*/*F*~0~) and *K*~d~ is the dissociation constant for the Ca^2+^ dye complex. The value of *K*~d~ for fluo-4 was taken to be 1.1 μM ([@B43]). \[Ca^2+^\]~rest~ was taken as 100 nM ([@B19], [@B29]). In experiments where diastolic Ca^2+^ increased, *F*~0~ from the control condition was used for the calculation of *R* in subsequent images for each cell. The time constant of the \[Ca^2+^\]~i~-transient decay (τ~decay~) was evaluated by a monoexponential fit to the declining phase of the transient. All experiments were performed at room temperature (26--28°C).

### Statistical analysis.

All data are reported as means ± SE. Repeated-measures one-way ANOVA and two-tailed *t*-test were used with a *P* value \<0.05 taken as a measure of significance.

RESULTS
=======

### Altered intracellular localization and increased autophosphorylation of Pak1 at Thr423 by BK treatment of cardiac myocytes.

[Figure 1](#F1){ref-type="fig"} demonstrates the intracellular distribution of Pak1 as a function of the concentration levels of BK using immunofluorescence in fixed myocytes and confocal microscopy. Also shown is a phase-contrast image of the myocytes. In the control myocytes with no BK treatment ([Fig. 1](#F1){ref-type="fig"}, *lanes 1* and *2*), endogenous Pak1 demonstrated defined intracellular localizations. As we previously reported ([@B22]), endogenous Pak1 localizes to the Z-line, intercalated disc, and cell and nuclear membranes. When the cardiac myocytes were treated with BK at low (0.1 μM; [Fig. 1](#F1){ref-type="fig"}, *lanes 3* and *4*) to high concentrations (1.0 and 10 μM; [Fig. 1](#F1){ref-type="fig"}, *lanes 5* and *6* and *lanes 6* and *7*), the endogenous Pak1 changed its intracellular distribution. BK treatment abolished the membrane localization and striated pattern of the endogenous Pak1 with the translocation of Pak1 occurring in a concentration-dependent manner. Thus the confocal images indicate that the striated localization of Pak1 became blurred when myocytes were treated with BK at 0.1 μM and disappeared completely when myocytes were treated with BK at 1 and 10 μM. The phase-contrast images demonstrate that this was not due to an altered sarcomeric structure. We identified the same changes in Pak1 localization induced by BK in more than 20 myocytes for each treatment.

![Intracellular localization of endogenous p21-activated kinase-1 (Pak1) regulated by bradykinin (BK) in rat ventricle myocytes. *Lanes 1*, *3*, *5*, and *7*: confocal images with immunofluorescence signals for Pak1. *Lanes 2*, *4*, *6*, and *8*: transmitted light images of the myocytes. *Lanes 1* and *2*: control myocytes without BK treatment. *Lanes 3* and *4*: myocytes treated with 0.1 μM BK. *Lanes 5* and *6*: myocytes treated with 1 μM BK. *Lanes 7* and *8*: myocytes treated with 10 μM BK. For immunofluorescence, the primary antibody was from Santa Cruz (sc-881). The secondary antibody was FITC-conjugated anti-rabbit IgG from Sigma (F-9887).](zh40051093040001){#F1}

To further determine whether BK acts as an upstream agonist for Pak1 in adult rat cardiac myocytes, we measured autophosphorylated Pak1 ([Fig. 2](#F2){ref-type="fig"}) using Western blot analysis with an antiphosphopeptide antibody specific for Thr423 ([@B41]). Thr423 is localized in the activation loop of the catalytic domain, which is the most important phosphorylation site for Pak1 activation. When the myocytes were treated with BK from 0.1 to 10 μM, Pak1 autophosphorylation increased gradually, with significant increases at 1 and 10 μM of BK treatment ([Fig. 2](#F2){ref-type="fig"}, *A* and *B*).

![*A*: Western blot analysis of autophosphorylation of endogenous Pak1 in myocytes treated with BK at different concentrations. *A*, *lanes 1--4*: myocytes treated with BK at 0, 0.1, 1, and 10 μM, respectively, for 10 min. Pak1 autophosphorylation was detected by phospho (p)-specific (Pak1 Thr423) antibody. Total Pak1 served as an internal control. *B*: histogram showing increase of Pak1 Thr423 autophosphorylation normalized to total Pak1. Results shown are representative of 3 independent experiments. p-Pak1 Thr423 levels are expressed as percentage of total Pak1. \**P* \< 0.05 compared with control without BK exposure.](zh40051093040002){#F2}

### BK induced dephosphorylation of troponin I and PLB.

Our previous studies indicated that an adenoviral transfer of active Pak1 into adult rat cardiac myocytes induced the dephosphorylation of cTnI and myosin-binding protein C with no effect on myosin light chain phosphorylation ([@B22]). Here we tested whether an agonist-induced increase in Pak1 activity is also able to dephosphorylate cTnI. To test whether both BK and constitutively active Pak1 induce changes in the phosphorylation of cTnI, we cultured freshly isolated cardiac myocytes in DMEM plus 10% FBS for 2 h. The cells were then infected with AdPak1 or AdLacZ as control and were incubated in serum-free media overnight. The phosphorylation of cTnI was detected by metabolic labeling with \[^32^P\]orthophosphate. BK or Iso were added to the \[^32^P\] incorporation buffer to test their effect on the phosphorylation of cTnI. Myocytes infected with AdPak1 ([Fig. 3*A*](#F3){ref-type="fig"}, *lane 1*) demonstrated significantly reduced cTnI phosphorylation compared with those infected with control virus AdLacZ ([Fig. 3*A*](#F3){ref-type="fig"}, *lane 2*) or AdLacZ with 100 nM Iso ([Fig. 3*A*](#F3){ref-type="fig"}, *lane 3*). In myocytes infected with AdLacZ and treated with BK at 10 μM, the phosphorylation at cTnI was also significantly reduced ([Fig. 3*A*](#F3){ref-type="fig"}, *lane 4*). Data from a series of experiments are summarized in [Fig. 3*B*](#F3){ref-type="fig"}.

![BK-induced activation of Pak1 associated with dephosphorylation of cardiac troponin I (cTnI). *A*: inhibition of phosphorylation of cTnI by constitutively active Pak1 and by BK, as detected by \[^32^P\] incorporation: myocytes infected with adenovirus Pak1 (AdPak1; *lane 1*), myocytes infected with AdLacZ (control; *lane 2*), myocytes infected with AdLacZ and treated with 100 nM isoproterenol (Iso; *lane 3*), and myocytes infected with AdLacZ and treated with BK at 10 μM (*lane 4*). *B*: histogram showing dephosphorylation of cTnI induced by BK at 1 and 10 μM (*n* = 3). Signal intensity is given in arbitrary units. Results shown are measurements from 4 independent experiments. \**P* \< 0.05 compared with control without exposure to BK.](zh40051093040003){#F3}

Results of experiments shown in [Fig. 4*A*](#F4){ref-type="fig"}, in which we employed metabolic labeling of ATP with \[^32^P\], demonstrated that the treatment of myocytes with either 1 or 10 μM BK induced a dephosphorylation of PLB, compared with the myocytes without BK treatment. As illustrated in [Fig. 4*B*](#F4){ref-type="fig"}, BK also induced a decrease in the phosphorylation of PLB, also detected by an antiphosphopeptide antibody specific for Ser16. The data summarized in [Fig. 4*C*](#F4){ref-type="fig"} summarize the results of a series of experiments and indicate that BK is an effective agent in inducing the dephosphorylation of PLB.

![Bradykinin induced a reduction in phosphorylation of phospholamban (PLB) in cardiac myocytes. *A*: \[^32^P\] incorporation into PLB from control myocytes (*lane 1*) and from myocytes treated with 1 μM (*lane 2*) and 10 μM (*lane 3*) BK, respectively. Equal amounts of cardiac myocytes were plated in 35-mm culture dish. \[^32^P\] incorporation was carried out at room temperature for 30 min. At 30 min of incubation in buffer containing \[^32^P\]orthophosphate, BK was added and was incubated for 2 min more. Equal amounts of total protein were loaded in each sample lane as demonstrated by Coommassie blue staining. *B*: Western blot detection of PLB-Ser16 phosphorylation in control myocytes treated with 100 nM Iso (*lane 1*) and Western blot of proteins from myocytes treated with 100 nM Iso + 10 μM BK for 2 min (*lane 2*). *C*: histogram summarizing the effect of BK effect on PLB phosphorylation corresponding to lanes 1, 2, and 3 of \[^32^P\] incorporation shown in *A*. Results shown are from 3 independent experiments. \**P* \< 0.05 compared with control without exposure to BK.](zh40051093040004){#F4}

### Pak1 and PLB associate with PP2A.

We have previously reported evidence that Pak1 associates with PP2A ([@B22]). In the present experiments, coimmunoprecipitation experiments demonstrated a complex between Pak1-PP2A and PLB ([Fig. 5](#F5){ref-type="fig"}). The catalytic subunit of PP2A was detected in an immunoprecipitation product using the Pak1 antibody. Pak1 was also detected as an immunoprecipitation product pulled down by a PP2A antibody ([Fig. 5*A*](#F5){ref-type="fig"}). The catalytic subunit of PP2A was also detected in the immunoprecipitation product with an antibody against PLB ([Fig. 5*B*](#F5){ref-type="fig"}).

![Demonstration of protein phosphate 2A (PP2A) association with both Pak1 and PLB by immunoprecipitation (IP). *A*: PP2A association with Pak1 when Pak1 antibody was used in IP (*lane 1*), negative control with the same experimental conditions except without the primary antibody (*lane 2*), and Pak1 association with PP2A when PP2Ac antibody was used in IP. *B*: Western blotting showing the presence of both PP2Ac and PLB in IP products using a PLB antibody. A control with no PLB or PP2A antibody showed no staining.](zh40051093040005){#F5}

### Treatment with BK slows the relaxation of \[Ca^2+^\]~i~ transients in cardiac myocytes stimulated with Iso.

The effects of BK on the contractile function of cardiac myocytes have not been previously defined; however, one potential role of BK is in the modification of cellular Ca^2+^ fluxes. To test this hypothesis, we used fluo-4 fluorescence and laser-scanning confocal microscopy to measure changes in the \[Ca^2+^\]~i~ transient during field stimulation with and without a preincubation with 1 μM BK. [Figure 6*A*](#F6){ref-type="fig"} illustrates the response of an untreated adult rat ventricular myocyte to the application of 100 nM Iso in the perfusion with a significant increase in peak Ca^2+^ and faster τ~decay~. A myocyte pretreated with 1 μM BK ([Fig. 6*B*](#F6){ref-type="fig"}) showed an increase in the amplitude of the \[Ca^2+^\]~i~ transient but a blunted response of τ~decay~ to the Iso application. [Figure 6*C*](#F6){ref-type="fig"} shows that the average peak \[Ca^2+^\]~i~ transient in untreated cells under control conditions was 297 ± 39 nM and following Iso was 660 ± 101 nM (*n* = 7 cells from 3 hearts). In cells that were pretreated with 1 μM BK, the average \[Ca^2+^\]~i~ transient peak was 345 ± 45 nM under control conditions and, after Iso treatment, increased to 606 ± 147 nM (*n* = 9 cells from 3 hearts). [Figure 6*D*](#F6){ref-type="fig"} shows that the average value of τ~decay~ measured from the same records was similar between treatment groups under control conditions (−BK, 243 ± 19 ms; and +BK, 227 ± 15); however, the cells that had been pretreated with BK had a significantly slower τ~decay~ following the application of Iso (−BK, 105 ± 9 ms; and +BK, 162 ± 19 ms, *P* \< 0.05).

![Intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) transients recorded from representative field-stimulated single adult rat ventricular myocytes in control conditions and after application of 100 nM Iso in an untreated cell (*A*) and a cell pretreated for 20 min with 1 μM BK (*B*) are shown. Summaries of peak \[Ca^2+^\]~i~ transients (*C*) and the \[Ca^2+^\]~i~-transient time constant of decay (τ~decay~; *D*) from the same set of records are shown. Data are presented as means ± SE. \**P* \< 0.05 compared with control; \#*P* \< 0.05 compared with −BK.](zh40051093040006){#F6}

DISCUSSION
==========

Our results provide the first evidence that Pak1 is a functionally significant downstream signaling molecule in a cascade initiated by the receptor binding of BK in adult cardiac myocytes. We demonstrated that Pak1 activity and its intracellular localization are regulated by BK in these myocytes. Moreover, both active Pak1 and BK promoted the dephosphorylation of PLB and cTnI and slowed the fall in Ca^2+^ during myocyte contractions stimulated by Iso. These findings significantly extend our previous investigation using an adenoviral transfer of Pak1 cDNA. In those studies ([@B22]), we reported evidence that the presence of active Pak1 is able to depress myofilament phosphorylation most likely through the activation of phosphatase PP2A ([@B22]). Our studies on Pak1 activation provide new evidence on mechanisms by which BK is cardioprotective. Previous studies in our laboratory ([@B1]) as well as others ([@B46]) have linked increases in myofilament Ca^2+^ sensitivity (a result of cTnI dephosphorylation) with resistance to cardiac stressors. The dephosphorylation of PLB would be expected to hinder the maladaptive SR Ca^2+^ load, a factor in ischemia-reperfusion injury ([@B38]). The results presented in [Fig. 6](#F6){ref-type="fig"} indicate that BK treatment induces a resistance to β-adrenergic stimulation in the cellular Ca^2+^ flux response, potentially by a slowed reuptake of Ca^2+^ to the SR or an extrusion from the cell or increased by an intracellular Ca^2+^ buffering. Along these lines, we recently reported that the activation of Pak1 by the drug FTY720 and sphingosine-1-phosphate are able to prevent ischemia-reperfusion-induced arrhythmias ([@B12]).

There is evidence from studies in noncardiac cells that support our findings. Studies in fibroblasts first suggested an activation of Pak1 by BK. Treatment of the fibroblasts with BK produced the same morphological change as the expression of constitutively active cdc42Hs, which is an upstream controller of Pak activity ([@B25]). Here we provide direct evidence that BK increased the phosphorylation of Thr423 of Pak1 in cardiac myocytes, and this increased autophosphorylation on Pak1 is correlated with the reduced phosphorylation of myofilament proteins and PLB. A connection between Pak1 and PP2A activity was first described in studies in neuronal tissue reported by Westphal et al. ([@B47]), who demonstrated that Pak1 and PP2A formed a signaling module in neuronal cells. This is also the case in cardiac myocytes ([@B22]). Other downstream kinase effectors in the heart for BK, especially protein kinase C (PKC), have been suggested but were poorly defined. Preconditioning following the treatment of hearts with BK was proposed to be related to PKC activation ([@B10]). Phospholipases C and D in rat ventricular myocytes were activated by BK, endothelin-1, and phenylephrine ([@B6], [@B7]). In a model of remote preconditioning, PKC inhibitors abolished the preconditioning effect ([@B48]). PKC was also suggested to be downstream of the adenosine and G~i~/G~o~ signaling pathways ([@B26]). Although there is evidence indicating that the signaling through PKC may be activated by BK, our data support the idea that the net effect of BK may reflect a balance between the activation of the activity of kinases and phosphatases.

Our finding of a BK-related activation of PP2A has important implications with regard to earlier studies in cardiac myocytes in which it was demonstrated that adenosine and acetylcholine signaling through G~i~/G~o~ may regulate the activity of PP2A without a significant effect on cAMP accumulation ([@B17], [@B18], [@B37]). These studies suggested an uncharacterized mechanism that regulates the activity of PP2A in response to adenosine and cholinergic stimulation. Our data indicate that the activation of Pak1 could be that mechanism ([@B22]). The physical association of Pak1 with PP2A in the heart suggested that Pak1 may execute its function through PP2A. The activity of PP2A is regulated by tyrosine phosphorylation ([@B5]), methylation ([@B45]), a large family of regulatory B subunits ([@B34]), and an autophosphorylation-regulated protein kinase ([@B16]). Recent studies of ours and others have also indicated that Pak1 activity has antiandrenergic effects ([@B21]) in the heart and may regulate some cardioprotective factors. Rac1/Pak1 activity is linked to the generation of nitric oxide ([@B39]) and cGMP ([@B15]), both of which have cardioprotective effects. Pak1 is also involved in the generation of reactive oxygen species, which is currently believed to have an important role in both the pre- and postconditioning effect of the heart during ischemia.

We think that the signaling mechanism in the transduction between BK receptor binding in cardiac myocytes and Pak1 activation is through G~i~. In the heart, signaling through G~i~ is associated with the dephosphorylation of cTnI and PLB ([@B30]). Acetylcholine and adenosine, which signal through G~i~, have also been demonstrated to induce an effect similar to BK on protein dephosphorylation in cardiac myocytes ([@B17], [@B18], [@B30]). G~i~ has also been demonstrated to couple to BK receptors ([@B27], [@B28]), and the inhibition of G~i~ protein by low-density lipoprotein attenuates the BK-stimulated release of endothelial-derived nitric oxide ([@B27]). In leukocytes, the activation of Pak1 is regulated by pertussis toxin treatment ([@B23]). Moreover, in fibroblasts, Cdc42 may be a component in the BK-initiated signaling cascade ([@B25]). Further support for the existence of this signaling cascade comes from the observation that the expression of constitutively active Cdc42 in fibroblasts can override the inhibitory effect of pertussis toxin on lysophosphatidic acid-induced cell morphological changes ([@B44]). Our recent studies also indicated that the activation of sphingosine-1 phosphate receptors in the heart may deliver signals to Pak1 via the inhibitory G proteins ([@B12]).

Yet, understanding the coordination of the molecular events in response to BK and other agonist stimulation in cardiac myocytes remains a significant challenge. When compared with PKA and PKC, Pak1 is a novel Ser/Thr protein kinase. BK and Pak1 may represent two interrelated coordinators that regulate both myofilament activities and cellular Ca^2+^ fluxes. Although there is strong evidence indicating that Pak1 is activated by BK, other signaling factors may also be partially responsible for the BK effect in cardiomyocytes. For example, BK had a broader effect in the reduction of the phosphorylation of myofilament proteins in adult rat ventricular myocytes than Pak1. The expression of the constitutively active Pak1 in the myocytes had no effect on the phosphorylation of cardiac troponin T and myosin regulatory light chain (MLC~2v~) ([@B22]), whereas in the present experiments, BK induced the dephosphorylation of cardiac troponin T and MLC~2~ (data not shown), as well as cTnI and myosin binding protein C. A further complication is that the Pak1 family consists of six members, and their functional role in cardiac muscle cells is just beginning to be understood. A further investigation of the regulation of Pak1 activity in cardiac muscle is likely to provide important data regarding both the short-term and long-term control of cardiac excitation and contraction.
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